Lilly, Sigilon Therapeutics Report Strategic Partnership to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes; Sigilon To Receive $63M Up Front And Lilly To Make An Undisclosed Equity Investment In Sigilon